A Study of Weekly Oral Dose of Ecnoglutide (VRB-101) for Weight Maintenance in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities
NCT07553299 on ClinicalTrials.gov · last registry update 2026-10-13
Stopped early, having planned 8 participants. The sponsor logged completion for 11 September 2026. Primary outcome, as filed: To identify the dose of VRB-101 for weight maintenance. ecnoglutide is not approved in the US for anything yet, so this is a drug in development rather than an established treatment being extended. The registry entry has been edited 3 times since then.
- Status
- TERMINATED
- Phase
- P2
- Drug
- ecnoglutide
- Sponsor
- Verdiva Bio Dev Limited
- Sponsor type
- Industry
- Enrollment
- 8
- Started
- 2026-06-12
- Primary completion
- 2026-09-11 actual
Observed history
Every change this record has made since we started watching it. ClinicalTrials.gov shows only the current value. When a field is edited the previous one is overwritten and nothing is published to say so, so this history exists only because someone was recording it at the time.
| Detected | Change | Detail |
|---|---|---|
| 2026-10-13 | Status changed | ACTIVE_NOT_RECRUITING → TERMINATED |
| 2026-10-13 | Reporting date moved | 2026-11-30 → 2026-09-11 2 months earlier |
| 2026-10-13 | Enrollment changed | 120 → 8 (-112) participants |
Primary outcome
To identify the dose of VRB-101 for weight maintenance
Conditions studied
Obesity · Overweight · Weight Maintenance
Every field above is taken directly from the registry record. See all detected changes across the class, or the ecnoglutide page for this molecule’s full trial and approval history.